Regeneron's Garetosmab Receives FDA Priority Review for Rare Bone Disorder FOP
The FDA has accepted Regeneron's Biologics License Application for garetosmab to treat fibrodysplasia ossificans progressiva, granting Priority Review with a target action date of August 2026. The application is supported by Phase 3 OPTIMA trial data.